BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 20728697)

  • 1. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
    Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
    Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and cellular mechanisms of anthracycline cardiotoxicity.
    Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB
    Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline Chemotherapy and Cardiotoxicity.
    McGowan JV; Chung R; Maulik A; Piotrowska I; Walker JM; Yellon DM
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):63-75. PubMed ID: 28185035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.
    Geisberg CA; Sawyer DB
    Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy.
    Nishi M; Wang PY; Hwang PM
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2648-2660. PubMed ID: 34587760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.
    Lindsey ML; Lange RA; Parsons H; Andrews T; Aune GJ
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1379-89. PubMed ID: 25217655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention].
    Andrieu-Abadie N
    Therapie; 2004; 59(1):121-6. PubMed ID: 15199678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
    Doroshow JH
    Curr Pharm Biotechnol; 2012 Aug; 13(10):1949-56. PubMed ID: 22352729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.
    Maulik A; Davidson SM; Piotrowska I; Walker M; Yellon DM
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):245-253. PubMed ID: 29766336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
    Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
    Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
    Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
    Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
    Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.